2篇
您的检索式：作者名="Shurui Fan"
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | The highly selective catalytic hydrogenation of CO_(2)to CO over transition metal nitrides显示文摘Three transition metal-like facet centered cubic structured transition metal nitrides,γ-Mo_(2)N,β-W_(2)N andδ-NbN,are synthesized and applied in the reaction of CO_(2)hydrogenation to CO.Among the three nitride catalysts,theγ-Mo_(2)N exhibits superior activity to target product CO,which is 4.6 and 76 times higher than the other two counterparts ofβ-W_(2)N andδ-NbN at 600℃,respectively.Additionally,γ-Mo_(2)N exhibits excellent stability on both cyclic heating-cooling and high space velocity steady state operation.The deactivation degree of cyclic heating-cooling evaluation after 5 cycles and long-term stability performance at 773 and 873 K in 50 h are all less than 10%.In-situ XRD and kinetic studies suggest that theγ-Mo_(2)N itself is able to activate both of the reactants CO_(2)and H_(2).Below 400℃,the reaction mainly occurs at the surface ofγ-Mo_(2)N catalyst.CO_(2)and H_(2)competitively adsorbe on the surface of catalyst and CO_(2)is the relatively stronger surface adsorbate.At a higher temperature,the interstitial vacancies of theγ-Mo_(2)N can be reversibly filled with the oxygen from CO_(2)dissociation.Both of the surface and bulk phase sites ofγ-Mo_(2)N participate in the high temperature CO_(2)hydrogenation pathway. | Yichao Wu Zhiwei Xie Xiaofeng Gao Xian Zhou Yangzhi Xu Shurui Fan Siyu Yao Xiaonian Li Lili Lin | 2022 | Chinese Journal of Chemical Engineering2022，35，3： | 0 |
| 2 | Intratumoral CD103+CD8+T cells predict response to neoadjuvant chemoimmunotherapy in advanced head and neck squamous cell carcinoma显示文摘Background Immune cell heterogenicity is known to determine the therapeutic response to cancer progression.Neoadjuvant chemoimmunotherapy(NACI)has shown clinical benefits in some patients with advanced head and neck squamous cell carcinoma(HNSCC),but the underlying mechanism behind this clinical response is unknown.The efficacy of NACI needs to be potentiated by identifying accurate biomarkers to predict clinical responses.Here,we attempted to identify molecules predicting NACI response in advanced HNSCC.Methods We performed combined single-cell RNA sequencing(scRNA-seq)and multiplex immunofluorescence(mIHC)staining with tumor samples derived from NACI-treated HNSCC patients to identify a new tumor-infiltrating cell(TIL)subtype,CD103+CD8+TILs,associated with clinical response,while both in vitro and in vivo assays were carried out to determine its antitumor efficiency.The regulatory mechanism of the CD103+CD8+TILs population was examined by performing cell-cell interaction analysis of the scRNA-seq data and spatial analysis of the mIHC images.Results We established intratumoral CD103+CD8+TILs density as a determinant of NACI efficacy in cancers.Our scRNA-seq results indicated that the population of CD103+CD8+TILs was dramatically increased in the responders of NACI-treated HNSCC patients,while mIHC analysis confirmed the correlation between intratumoral CD103+CD8+TILs density and NACI efficacy in HNSCC patients.Further receiver operating characteristic curve analysis defined this TIL subset as a potent marker to predict patient response to NACI.Functional assays showed that CD103+CD8+TILs were tumor-reactive T cells,while programmed cell death protein-1(PD-1)blockade enhanced CD103+CD8+TILs cytotoxicity against tumor growth in vivo.Mechanistically,targeting the triggering receptor expressed on myeloid cells 2-positive(TREM2+)macrophages might enhance the population of CD103+CD8+TILs and facilitate antitumor immunity during NACI treatment.Conclusions Our study highlights the impact of intratumoral CD103+CD8+TILs density on NACI efficacy in different cancers,while the efforts to elevate its population warrant further clinical investigation. | Siqi Ren Tianjun Lan Fan Wu Suling Chen Xue Jiang Chuying Huo Zitian Li Shule Xie Donghui Wu Ruixin Wang Yanyan Li Lin Qiu Guoxin Huang Shurui Li Xiaojuan Wang Meifeng Cen Tingting Cai Zhaoyu Lin Jinsong Li Bowen Li | 2023 | Cancer Communications2023，43，10： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员